Definium Therapeutics has published new data showing that its LSD-derived drug, DT120, reduced anxiety in patients across a second large trial. The company now stands ready to pursue what could be the first approval of a psychedelic drug for anxiety.
The 12-week study compared patients who took a 100-microgram dose of DT120 against those who received a placebo. Patients on the drug saw their score on the Hamilton Anxiety Rating Scale drop by 9.8 points, while those on placebo dropped by 4.7 points. The difference of 5.1 points is similar to what was seen in Definium’s first late-stage anxiety study.
The Trial Design
The study ran for 12 weeks. Patients were given a 100-microgram dose of DT120 or a placebo, and their anxiety was measured using the Hamilton Anxiety Rating Scale at set intervals.
The scale measures symptoms of anxiety, and a drop of 5.1 points between the drug group and the placebo group is notable. Definium describes the result as larger than what has been seen with many other anxiety therapies, though it notes that comparing results across studies is difficult.
Why This Matters
Definium is among the first wave of biotech companies nearing regulatory approval for psychedelic therapies. These treatments have gained attention because they seem to produce rapid benefits, unlike traditional options like antidepressants, which can take weeks to become effective.
In the latest trial, Definium said patients experienced changes as early as the second day after dosing. That timing fits the broader appeal of psychedelic therapies, which appear to offer faster relief than conventional drugs.
What Happens Next
The company’s next step is regulatory approval. If granted, DT120 would become the first approved psychedelic drug for anxiety.
“The effects of traditional options like antidepressants take weeks to kick in.”
That framing comes from the company’s description of the trial, not a direct quotation.
Key Facts
- Drug: DT120, derived from LSD
- Dose: 100 micrograms
- Trial duration: 12 weeks
- Score drop (drug): 9.8 points
- Score drop (placebo): 4.7 points
- Difference: 5.1 points
The Path Forward
The data from the second trial strengthens Definium’s position. Consistency across two large studies removes some of the uncertainty that often accompanies early-stage research.
Approval remains the final hurdle. If reached, it would mark a significant moment for psychedelic medicine, which has spent years building evidence of clinical value.
For patients with anxiety, the potential payoff is straightforward: a treatment that works faster than existing options, with data from multiple large studies supporting it.
The consistency across both trials is the strongest argument for Definium’s position. The second trial’s results mirror the first, with a similar magnitude of effect and an early onset that fits the pattern seen in the earlier study. That pattern is what separates psychedelic therapies from traditional options like antidepressants, which take weeks to become effective.
Approval remains the final hurdle. If reached, it would mark a significant moment for psychedelic medicine, which has spent years building evidence of clinical value.
For patients with anxiety, the potential payoff is straightforward: a treatment that works faster than existing options, with data from multiple large studies supporting it.
See the a run of 36 images at STAT.